Last reviewed · How we verify
Topical application of 0.05% Clobetasol propionate
Topical application of 0.05% Clobetasol propionate is a Small molecule drug developed by Combined Military Hospital (CMH) institute of Medical Sciences Bahawalpur Pakistan. It is currently in Phase 1 development.
At a glance
| Generic name | Topical application of 0.05% Clobetasol propionate |
|---|---|
| Sponsor | Combined Military Hospital (CMH) institute of Medical Sciences Bahawalpur Pakistan |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Treatment of Bullous Pemphigoid With Avdoralimab (IPH5401), an Anti-C5aR1 Monoclonal Antibody (PHASE2)
- Targeted Investigation of Microbiome 2 Treat Atopic Dermatitis (TIME-2) (PHASE1)
- Effectiveness of Micro-needling With 5 Fluorouracil Versus Potent Topical Steroids in the Treatment of Limited Vitiligo (EARLY_PHASE1)
- Photobiomodulation, Er:YAG Laser, and Clobetasol in the Treatment of Oral Lichen Planus. (NA)
- Laser vs Clobetasol for Lichen Sclerosus (PHASE3)
- Treatment of Vulvar Lichen Sclerosus With Corticosteroid Ointment, Calcineurin Inhibitor Ointment, and Platelet-Rich Plasma (PRP) Therapy. (NA)
- ZINCLO-HAND: Zinc and Clobetasol for the Prevention of Regorafenib-Induced Hand-Foot Skin Reaction (NA)
- Mucoadhesive Modified-Release Formulations for the Topical Treatment of Symptomatic Oral Lichen Planus (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Topical application of 0.05% Clobetasol propionate CI brief — competitive landscape report
- Topical application of 0.05% Clobetasol propionate updates RSS · CI watch RSS
- Combined Military Hospital (CMH) institute of Medical Sciences Bahawalpur Pakistan portfolio CI
Frequently asked questions about Topical application of 0.05% Clobetasol propionate
What is Topical application of 0.05% Clobetasol propionate?
Topical application of 0.05% Clobetasol propionate is a Small molecule drug developed by Combined Military Hospital (CMH) institute of Medical Sciences Bahawalpur Pakistan.
Who makes Topical application of 0.05% Clobetasol propionate?
Topical application of 0.05% Clobetasol propionate is developed by Combined Military Hospital (CMH) institute of Medical Sciences Bahawalpur Pakistan (see full Combined Military Hospital (CMH) institute of Medical Sciences Bahawalpur Pakistan pipeline at /company/combined-military-hospital-cmh-institute-of-medical-sciences-bahawalpur-pakistan).
What development phase is Topical application of 0.05% Clobetasol propionate in?
Topical application of 0.05% Clobetasol propionate is in Phase 1.